Clinical Trials Browser

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Fallopian Tube Neoplasms, Ovarian Neoplasms

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Prostatic Neoplasms

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma, Recurrence

Carcinoma, Non-Small-Cell Lung

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Prostate Cancer Metastatic

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Multiple Myeloma

Multiple Myeloma

Carcinoma, Non-Small-Cell Lung

Multiple Myeloma, Recurrence

Multiple Myeloma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Multiple Myeloma

Multiple Myeloma

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma, Recurrence

Prostatic Neoplasms, Castration-Resistant

Multiple Myeloma, Recurrence

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Multiple Myeloma

Prostatic Neoplasms

Multiple Myeloma

Clinical Trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

TroFuse-022

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

MagnetisMM-6

MK-5684-004

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

CARTITUDE-2

CARTITUDE-4

CARTITUDE-5

MajesTEC-3

A Study of Daratumumab

MonumenTAL-3

MajesTEC-7

MajesTEC-9

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

aMMbition

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

EPCORE™ NHL-2

OMAHA-003

OLYMPIA-4

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

EXCALIBER-RRMM

PLYCOM

MK-2870-009

SUCCESSOR-2

DREAMM-3

MK-3475-01E

MAGNETISMM-5

iMMagine-3

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

SUCCESSOR-1

MK-5684-01A

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

MK-3475-06B

CAMMA 1

MK-5684-001

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)